Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Fowler

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
Neurobiology of Disease|June 8, 2022
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-βMarcela Cespedes, Kelly R Jacobs, Paul Maruff, et al.
Alzheimer'S Research & Therapy|December 3, 2025
Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderlyMadison I J Honey, Ingrid S van Maurik, Argonde C van Harten, et al.
Journal of Alzheimer'S Disease : JAD|June 24, 2025
Amyloid-β protein precursor fragments in urine: Potential biomarkers for the early detection of mild cognitive impairment and dementiaJingyu Zhu, Xiao Xiao, Xiaotong Chen, et al.
Journal of Alzheimer'S Disease : JAD|November 25, 2017
Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay PlatformsJames D Doecke, Alan Rembach, Victor L Villemagne, et al.
Alzheimer'S Research & Therapy|November 20, 2015
Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodologyAlan Rembach, Lisbeth A Evered, Qiao-Xin Li, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 16, 2013
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's diseaseAlan Rembach, Noel G Faux, Andrew D Watt, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) studyQiao-Xin Li, Victor L Villemagne, James D Doecke, et al.
Annals of Neurology|January 26, 2026
When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 YearsRodrigo Cánovas, Timothy Cox, Vincent Doré, et al.
Nature Communications|September 19, 2019
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's diseaseXavier Hadoux, Flora Hui, Jeremiah K H Lim, et al.
Nature Communications|January 29, 2025
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatmentKatharina Bolsewig, Eline A J Willemse, Pascual Sánchez-Juan, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
Neurobiology of Disease|June 8, 2022
Systemic perturbations of the kynurenine pathway precede progression to dementia independently of amyloid-βMarcela Cespedes, Kelly R Jacobs, Paul Maruff, et al.
Alzheimer'S Research & Therapy|December 3, 2025
Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderlyMadison I J Honey, Ingrid S van Maurik, Argonde C van Harten, et al.
Journal of Alzheimer'S Disease : JAD|June 24, 2025
Amyloid-β protein precursor fragments in urine: Potential biomarkers for the early detection of mild cognitive impairment and dementiaJingyu Zhu, Xiao Xiao, Xiaotong Chen, et al.
Journal of Alzheimer'S Disease : JAD|November 25, 2017
Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay PlatformsJames D Doecke, Alan Rembach, Victor L Villemagne, et al.
Alzheimer'S Research & Therapy|November 20, 2015
Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodologyAlan Rembach, Lisbeth A Evered, Qiao-Xin Li, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 16, 2013
Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's diseaseAlan Rembach, Noel G Faux, Andrew D Watt, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) studyQiao-Xin Li, Victor L Villemagne, James D Doecke, et al.
Annals of Neurology|January 26, 2026
When Does Alzheimer's Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ-PET Centiloid 15, Mean Age of 66 YearsRodrigo Cánovas, Timothy Cox, Vincent Doré, et al.
Nature Communications|September 19, 2019
Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's diseaseXavier Hadoux, Flora Hui, Jeremiah K H Lim, et al.
Nature Communications|January 29, 2025
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatmentKatharina Bolsewig, Eline A J Willemse, Pascual Sánchez-Juan, et al.
Pageof 17